Opendata, web and dolomites

FACTs

Fast Acting Virus Control Strategies for Production Animal Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FACTs project word cloud

Explore the words cloud of the FACTs project. It provides you a very rough idea of what is the project "FACTs" about.

feedlot    bvd    return    animals    difficult    beef    decreased    launched    plan    bovine    infected    herd    infect    cattle    arrival    unable    antigenic    detect    introduction    opinion    treatment    inadequate    administered    shed    disruptive    biotech    billions    brazil    exposed    immune    host    globally    leaders    euros    company    contracts    efficiency    sign    susceptibility    successful    sales    costing    diarrhoea    rapid    calves    until    utero    investment    belgian    house    kols    virus    signed    expressed    endemic    pi    consult    supportive    clinical    disease    virovet    initially    facts    minimize    shedding    secondary    conduct    drug    vaccination    regulatory    amounts    maximize    trl    massive    infection    vaccines    million    investors    industry    business    peak    predicted    viral    150    continuous    form    sheet    separated    variability    standard    feed    assist    market    alone    producing    persistently    reduce    refinement    contamination    auction    added    labour    time    markets    finalized    conventional    stage    introducing    ing    prevent    mortality   

Project "FACTs" data sheet

The following table provides information about the project.

Coordinator
ARATANA THERAPEUTICS NV 

Organization address
address: AMBACHTENLAAN 1
city: HEVERLEE
postcode: 3001
website: www.okapi-sciences.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website http://www.virovet.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARATANA THERAPEUTICS NV BE (HEVERLEE) coordinator 50˙000.00

Map

 Project objective

The objective of the FACTs project is to sign a term sheet with investors for ViroVet, an emerging Belgian biotech company, aimed at developing and introducing a disruptive treatment for bovine viral diarrhoea (BVD) in beef cattle. BVD is a globally endemic disease of cattle costing the industry billions of Euros every year in the form of increased mortality, decreased feed efficiency and increased susceptibility to secondary disease. Conventional BVD vaccines are unable to fully control the disease due to antigenic variability of the virus and inadequate host immune response to vaccination. BVD virus can infect calves in utero leading to persistently infected (PI) animals that are difficult to detect but that shed massive amounts of virus, resulting in continuous contamination of the herd. The product will initially be launched in the EU and US, with other large beef-producing markets, such as Brazil, also considered. It will be administered to cattle upon arrival at the feedlot or auction house, which is a time of high susceptibility to infection. The drug will prevent exposed animals from developing clinical disease and will reduce viral shedding by PI animals until they are identified and separated from the herd. The drug will be added to standard processing procedures to minimize labour time and cost. The BVD project is in TRL-6 stage and is predicted to reach market in 6-8 years’ time with peak sales of €150 million in the EU and US alone. Key opinion leaders (KOLs) are supportive of the product and a number of investors have expressed their interest. In Phase I, ViroVet will conduct market research and consult with KOLs in Europe and in other major beef markets to ensure successful introduction of the product. A comparative analysis of regulatory requirements will assist in the refinement of the business plan that will minimize time to market and maximize rapid return on investment. Contracts with investors will be finalized and a term sheet will be signed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More